171 related articles for article (PubMed ID: 38530426)
1. Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era.
Wang R; Tan G; Lei D; Li Y; Gong J; Tang Y; Pang H; Luo H; Qin B
J Cancer Res Clin Oncol; 2024 Mar; 150(3):158. PubMed ID: 38530426
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
4. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S
BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Xia Z; Zhang J; Chen W; Zhou H; Du D; Zhu K; Chen H; Meng J; Yang J
Infect Dis Poverty; 2023 Sep; 12(1):87. PubMed ID: 37736699
[TBL] [Abstract][Full Text] [Related]
8. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Hu X; Li R; Li Q; Zang M; Yuan G; Chen J
BMC Infect Dis; 2022 Jul; 22(1):614. PubMed ID: 35836207
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
[TBL] [Abstract][Full Text] [Related]
10. Management of HBV reactivation in non-oncological patients.
Pisaturo M; Di Caprio G; Calò F; Portunato F; Martini S; Coppola N
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):611-624. PubMed ID: 30058401
[TBL] [Abstract][Full Text] [Related]
11. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
Front Immunol; 2022; 13():892618. PubMed ID: 35711409
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
Sayar S; Kürbüz K; Kahraman R; Öztürk O; Çalışkan Z; Doğanay HL; Özdil K
Turk J Gastroenterol; 2020 Jul; 31(7):522-528. PubMed ID: 32897226
[TBL] [Abstract][Full Text] [Related]
13. Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation.
Elsebaey MA; Elbedewy TA; Elashry H; Elrefaey W; Elshweikh SA; Elhadidy AA; Shalaby NA; Elsokkary AM; Elashtokhy HEA; Abo-Amer YE; Abo-Elfetoh AR; Hassanien SEA; Fouad A; Abdellatif RS; Ismail AAM
Medicine (Baltimore); 2022 Nov; 101(47):e31962. PubMed ID: 36451458
[TBL] [Abstract][Full Text] [Related]
14. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
[TBL] [Abstract][Full Text] [Related]
15. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.
Jang JW
World J Gastroenterol; 2014 Jun; 20(24):7675-85. PubMed ID: 24976705
[TBL] [Abstract][Full Text] [Related]
17. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
[TBL] [Abstract][Full Text] [Related]
18. [Effect of HBV DNA load on the safety and prognosis of systematic therapy in advanced hepatocellular carcinoma].
Zheng XR; Peng JX; Song X; Liu B; Zhong C; Chen XY; Zhang BX; Peng L; Zhu KS; Xie C
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1160-1167. PubMed ID: 38583047
[No Abstract] [Full Text] [Related]
19. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.
Shen J; Wang X; Wang N; Wen S; Yang G; Li L; Fu J; Pan X
Front Cell Infect Microbiol; 2023; 13():1179689. PubMed ID: 37197205
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
